Literature DB >> 19016543

Construction of an efficient evaluative instrument for myasthenia gravis: the MG composite.

Ted M Burns1, Mark R Conaway, Gary R Cutter, Donald B Sanders.   

Abstract

We assessed the performance of items from the Quantitative Myasthenia Gravis (QMG), MMT (Manual Muscle Test), and MG-ADL (Myasthenia Gravis - Activities of Daily Living) scales, using data from two recently completed treatment trials of generalized MG. Items were selected that were relevant to manifestations of MG, meaningful to both the physician and the patient, and responsive to clinical change. After the 10 items were chosen, they were weighted based on input from MG experts from around the world, considering factors such as quality of life, disease severity, risk, prognosis, validity, and reliability. The MG Composite is easy to administer, takes less than 5 minutes to complete, and requires no equipment. Weighting of the response options of the 10 items should result in ordinal scores that better represent MG status and are more responsive to meaningful clinical change. To better determine its suitability for clinical use and for treatment trials, the MG Composite will be tested prospectively at several academic medical centers and will be used as a secondary measure of efficacy in pending clinical trials of MG.

Entities:  

Mesh:

Year:  2008        PMID: 19016543     DOI: 10.1002/mus.21185

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  18 in total

Review 1.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  The MG Composite: A valid and reliable outcome measure for myasthenia gravis.

Authors:  Ted M Burns; Mark Conaway; Donald B Sanders
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

3.  Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients.

Authors:  Alberto Raggi; Carlo Antozzi; Fulvio Baggi; Matilde Leonardi; Lorenzo Maggi; Renato Mantegazza
Journal:  Neurol Sci       Date:  2017-08-05       Impact factor: 3.307

Review 4.  History of Myasthenia Gravis Revisited.

Authors:  Feza Deymeer
Journal:  Noro Psikiyatr Ars       Date:  2020-11-07       Impact factor: 1.339

5.  Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials.

Authors:  Charlotte Vrinten; Alexander F Lipka; Erik W van Zwet; Kirsten J M Schimmel; Martina C Cornel; Marja R Kuijpers; Yechiel A Hekster; Stephanie S Weinreich; Jan J G M Verschuuren
Journal:  BMJ Open       Date:  2015-07-16       Impact factor: 2.692

6.  Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development.

Authors:  Anne Taraldsen Heldal; Geir Egil Eide; Fredrik Romi; Jone Furlund Owe; Nils Erik Gilhus
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

7.  A conceptual framework for evaluating impairments in myasthenia gravis.

Authors:  Carolina Barnett; Vera Bril; Moira Kapral; Abhaya Kulkarni; Aileen M Davis
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

8.  Development and validation of the Myasthenia Gravis Impairment Index.

Authors:  Carolina Barnett; Vera Bril; Moira Kapral; Abhaya Kulkarni; Aileen M Davis
Journal:  Neurology       Date:  2016-07-08       Impact factor: 9.910

9.  Fixation stability of the upward gaze in patients with myasthenia gravis: an eye-tracker study.

Authors:  Miharu Mihara; Atsushi Hayashi; Kazuya Fujita; Ken Kakeue; Ryoi Tamura
Journal:  BMJ Open Ophthalmol       Date:  2017-11-16

10.  Development of a Computerized Adaptive Test for Quantifying Chinese Medicine Syndrome of Myasthenia Gravis on Basis of Multidimensional Item Response Theory.

Authors:  Zhongyu Huang; Yunying Yang; Fengbin Liu; Lijuan Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.